Home / Recalls / STAQ Pharma, Inc. / D-0633-2022

D-0633-2022 Class I Terminated

Recalled by STAQ Pharma, Inc. — Denver, CO

Recall Details

Product Type
Drugs
Report Date
February 23, 2022
Initiation Date
February 3, 2022
Termination Date
September 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
905 Syringes

Product Description

HYDROmorphone HCl PF 10 mg/50 mL (0.2mg/mL) in NaCl, 50 mL in 50 mL Single Dose Syringe, Rx only, STAQ Pharma, Inc., Denver, CO 80239, NDC: 73177-0104-05.

Reason for Recall

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A

Distribution Pattern

CO, OH, and TX.

Code Information

Lot Number: 21104221A, Expiration date: 05-22-2022

Other recalls by STAQ Pharma, Inc.

  • D-0023-2026 Class III — Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL (October 9, 2025)
  • D-0024-2026 Class III — Ketamine Hydrochloride, 50mg/5 mL (10mg/mL), Injection for IV use, 50 mL syringe (October 9, 2025)
  • D-0025-2026 Class III — FentaNYL Citrate PF, 500mcg/50 mL (10mcg/mL) in NACL, Injection for IV use, 50 m (October 9, 2025)
  • D-0147-2024 Class II — ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injecti (November 29, 2023)
  • D-0634-2022 Class I — Morphine Sulfate PF 25 mg/25mL (1 mg/mL) in NaCl, 25 mL in 30 mL Single Dose Syr (February 3, 2022)